Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey

Uncontrollable bleeding is the leading cause of death in traumatically injured patients. The extent to which direct factor Xa inhibitors interfere with the applied resuscitation measures is presently unknown.

• Publication year

  2018

• Venue

  Transfusion

• Publication date

  2018-10-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/trf.14933PMID 30343500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome

  2017cited by this paper
• Effect of solvent/detergent‐treated pooled plasma on fibrinolysis in reconstituted whole blood

  2017cited by this paper
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

  2017cited by this paper
• Cause of trauma-induced coagulopathy

  2016cited by this paper
• Red Blood Cell Transfusion in the Emergency Department.

  2016cited by this paper
• Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

  2016cited by this paper
• Increased coagulation and fibrinolytic potential of solvent–detergent plasma: a comparative study between Omniplasma and fresh frozen plasma

  2016influential reference
• Advances in the understanding of trauma-induced coagulopathy.

  2016cited by this paper
• In vitro effects of different sources of fibrinogen supplementation on clot initiation and stability in a model of dilutional coagulopathy

  2016cited by this paper
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

  2015cited by this paper
• The “Death Diamond”: Rapid thrombelastography identifies lethal hyperfibrinolysis

  2015cited by this paper
• The pathogenesis of traumatic coagulopathy

  2015cited by this paper
• Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma.

  2015influential reference
• Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.

  2015cited by this paper
• Thromboelastogram Evaluation of the Impact of Hypercoagulability in Trauma Patients

  2014cited by this paper
• Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

  2014cited by this paper
• How I treat patients with massive hemorrhage.

  2014cited by this paper
• Prothrombin Complex Concentrate Versus Fresh-Frozen Plasma for Reversal of Coagulopathy of Trauma: Is There a Difference?

  2014cited by this paper
• Thromboelastometry and organ failure in trauma patients: a prospective cohort study

  2014cited by this paper
• In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban

  2013cited by this paper
• Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

  2013cited by this paper
• Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.

  2013cited by this paper
• Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI‐mediated inhibition of fibrinolysis

  2013cited by this paper
• Resuscitation fluids.

  2013cited by this paper
• Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With Rivaroxaban

  2013cited by this paper
• The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: An in vitro analysis of the impact of severe acidosis

  2013cited by this paper
• Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients

  2013cited by this paper
• Critical care in emergency department: massive haemorrhage in trauma

  2012cited by this paper
• Tranexamic Acid

  2012cited by this paper
• Characterization of platelet dysfunction after trauma

  2012cited by this paper
• Tranexamic Acid A Review of its Use in the Treatment of Hyperfibrinolysis

  2012cited by this paper
• Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial

  2012cited by this paper
• The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases.

  2011cited by this paper
• Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.

  2010cited by this paper
• Thrombin generation, fibrin clot formation and hemostasis.

  2008cited by this paper
• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  2008cited by this paper
• Thrombin generation and fibrin clot structure.

  2007cited by this paper
• Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers

  2007cited by this paper
• A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

  2006cited by this paper
• Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.

  1993cited by this paper
• Fibrin Formed in Plasma is Composed of Fibers More Massive than those Formed from Purified Fibrinogen

  1988cited by this paper
• Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen.

  1983cited by this paper

• Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro

  2022cites this paper
• Fixed dosing of Prothrombin Complex Concentrate

  2022cites this paper
• In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra

  2022cites this paper
• DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.

  2022cites this paper
• Efficacy of Different Fluid Resuscitation Methods on Coagulation Function of Rats with Traumatic Hemorrhagic Shock.

  2020cites this paper
• Emergencies on direct oral anticoagulants

  2020cites this paper
• Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

  2020cites this paper